tiprankstipranks
Trending News
More News >
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
US Market

Caris Life Sciences, Inc. (CAI) Stock Forecast & Price Target

Compare
125 Followers
See the Price Targets and Ratings of:

CAI Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Caris
Life Sciences, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CAI Stock 12 Month Forecast

Average Price Target

$38.40
▲(43.50% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Caris Life Sciences, Inc. in the last 3 months. The average price target is $38.40 with a high forecast of $45.00 and a low forecast of $28.00. The average price target represents a 43.50% change from the last price of $26.76.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","46":"$46","30.25":"$30.3","35.5":"$35.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,30.25,35.5,40.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.05,27.50769230769231,28.965384615384615,30.423076923076923,31.880769230769232,33.33846153846154,34.79615384615384,36.253846153846155,37.71153846153846,39.169230769230765,40.62692307692308,42.08461538461539,43.54230769230769,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.05,27,27.95,28.9,29.85,30.8,31.75,32.7,33.65,34.6,35.55,36.5,37.45,{"y":38.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.05,26.2,26.35,26.5,26.650000000000002,26.8,26.95,27.1,27.25,27.4,27.55,27.7,27.85,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$38.40Lowest Price Target$28.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
Buy
Reiterated
12/10/25
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (NASDAQ: ESTA), Legend Biotech (NASDAQ: LEGN) and Caris Life Sciences, Inc. (NASDAQ: CAI)
Canaccord Genuity Analyst forecast on CAI
Canaccord Genuity
Canaccord Genuity
$28
Hold
4.63%
Upside
Initiated
12/02/25
Caris Life Sciences initiated with a Hold at CanaccordCaris Life Sciences initiated with a Hold at Canaccord
Bank of America Securities Analyst forecast on CAI
Bank of America Securities
Bank of America Securities
$37$39
Buy
45.74%
Upside
Reiterated
11/06/25
Caris Life Sciences, Inc. (CAI) Receives a Buy from Bank of America Securities
J.P. Morgan Analyst forecast on CAI
J.P. Morgan
J.P. Morgan
$40
Buy
49.48%
Upside
Reiterated
11/06/25
J.P. Morgan Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)3Q25 Recap: Nice Quarter of ASP Execution Even Excluding True-Ups; Remain Overweight
BTIG
$45
Buy
68.16%
Upside
Reiterated
11/06/25
Analysts Offer Insights on Healthcare Companies: Accuray (NASDAQ: ARAY), Evolus (NASDAQ: EOLS) and Caris Life Sciences, Inc. (NASDAQ: CAI)
Evercore ISI Analyst forecast on CAI
Evercore ISI
Evercore ISI
$40
Buy
49.48%
Upside
Reiterated
10/07/25
Caris Life Sciences added to 'Tactical Outperform' list at Evercore ISICaris Life Sciences added to 'Tactical Outperform' list at Evercore ISI
Citi
$34$42
Buy
56.95%
Upside
Reiterated
08/13/25
Citi Remains a Buy on Caris Life Sciences, Inc. (CAI)
Wolfe Research Analyst forecast on CAI
Wolfe Research
Wolfe Research
$32
Buy
19.58%
Upside
Initiated
07/14/25
Caris Life Sciences initiated with an Outperform at Wolfe ResearchCaris Life Sciences initiated with an Outperform at Wolfe Research
Guggenheim Analyst forecast on CAI
Guggenheim
Guggenheim
$32
Buy
19.58%
Upside
Initiated
07/13/25
Caris Life Sciences initiated with a Buy at GuggenheimCaris Life Sciences initiated with a Buy at Guggenheim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
Buy
Reiterated
12/10/25
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (NASDAQ: ESTA), Legend Biotech (NASDAQ: LEGN) and Caris Life Sciences, Inc. (NASDAQ: CAI)
Canaccord Genuity Analyst forecast on CAI
Canaccord Genuity
Canaccord Genuity
$28
Hold
4.63%
Upside
Initiated
12/02/25
Caris Life Sciences initiated with a Hold at CanaccordCaris Life Sciences initiated with a Hold at Canaccord
Bank of America Securities Analyst forecast on CAI
Bank of America Securities
Bank of America Securities
$37$39
Buy
45.74%
Upside
Reiterated
11/06/25
Caris Life Sciences, Inc. (CAI) Receives a Buy from Bank of America Securities
J.P. Morgan Analyst forecast on CAI
J.P. Morgan
J.P. Morgan
$40
Buy
49.48%
Upside
Reiterated
11/06/25
J.P. Morgan Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)3Q25 Recap: Nice Quarter of ASP Execution Even Excluding True-Ups; Remain Overweight
BTIG
$45
Buy
68.16%
Upside
Reiterated
11/06/25
Analysts Offer Insights on Healthcare Companies: Accuray (NASDAQ: ARAY), Evolus (NASDAQ: EOLS) and Caris Life Sciences, Inc. (NASDAQ: CAI)
Evercore ISI Analyst forecast on CAI
Evercore ISI
Evercore ISI
$40
Buy
49.48%
Upside
Reiterated
10/07/25
Caris Life Sciences added to 'Tactical Outperform' list at Evercore ISICaris Life Sciences added to 'Tactical Outperform' list at Evercore ISI
Citi
$34$42
Buy
56.95%
Upside
Reiterated
08/13/25
Citi Remains a Buy on Caris Life Sciences, Inc. (CAI)
Wolfe Research Analyst forecast on CAI
Wolfe Research
Wolfe Research
$32
Buy
19.58%
Upside
Initiated
07/14/25
Caris Life Sciences initiated with an Outperform at Wolfe ResearchCaris Life Sciences initiated with an Outperform at Wolfe Research
Guggenheim Analyst forecast on CAI
Guggenheim
Guggenheim
$32
Buy
19.58%
Upside
Initiated
07/13/25
Caris Life Sciences initiated with a Buy at GuggenheimCaris Life Sciences initiated with a Buy at Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Caris Life Sciences, Inc.

1 Month
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+16.67%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +16.67% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
-1.63%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -1.63% per trade.
1 Year
Success Rate
2/3 ratings generated profit
67%
Average Return
-2.87%
reiterated a buy rating last month
Copying Mark Massaro's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -2.87% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
-2.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of -2.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAI Analyst Recommendation Trends

Rating
Jul 25
Aug 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
0
4
4
Buy
6
12
14
8
3
Hold
0
1
2
4
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
13
16
16
12
In the current month, CAI has received 7 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. CAI average Analyst price target in the past 3 months is 38.40.
Each month's total comprises the sum of three months' worth of ratings.

CAI Financial Forecast

CAI Earnings Forecast

The previous quarter’s earnings for CAI were $0.08.
The previous quarter’s earnings for CAI were $0.08.

CAI Sales Forecast

The previous quarter’s earnings for CAI were $216.83M.
The previous quarter’s earnings for CAI were $216.83M.

CAI Stock Forecast FAQ

What is CAI’s average 12-month price target, according to analysts?
Based on analyst ratings, Caris Life Sciences, Inc.’s 12-month average price target is 38.40.
    What is CAI’s upside potential, based on the analysts’ average price target?
    Caris Life Sciences, Inc. has 43.50% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CAI a Buy, Sell or Hold?
          Caris Life Sciences, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Caris Life Sciences, Inc.’s price target?
            The average price target for Caris Life Sciences, Inc. is 38.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $28.00. The average price target represents 43.50% Increase from the current price of $26.76.
              What do analysts say about Caris Life Sciences, Inc.?
              Caris Life Sciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of CAI?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.